ABBVIE

Biologic drugs, derived from living cells, have revolutionized treatment for chronic conditions, offering better outcomes and fewer side effects. Their development and delivery face unique challenges, including sensitivity to substances in syringe systems and high viscosity. Trends toward self-injection and home care demand innovative delivery systems. Key elements for successful delivery include patient needs, drug efficacy, primary containment, and delivery devices. Human factors and material innovations, like cyclic olefin polymers, are crucial for effective, safe, and user-friendly biologic therapies.

Calico Labs, Google's $1.5B biotech startup, aims to extend human lifespan through advanced technologies and interdisciplinary research. Despite criticism for secrecy, it collaborates with institutions and companies, focusing on drug development, genetics, and machine learning to understand and combat aging.

PARP inhibitors show efficacy in BRCA1/2-mutated ovarian and breast cancers, with benefits extending to non-BRCA1/2-mutated cases. Clinical trials highlight olaparib's role in prolonging progression-free survival, especially in platinum-sensitive ovarian cancer. Ongoing research aims to identify biomarkers for PARP inhibitor responsiveness and understand resistance mechanisms.